Skip to main content

Table 1 Definitions of terms in included studies

From: Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis

Study Study design Setting Drug dose (mg/day) Median follow up (months) eGFR (ml/min/1.73 m2) Range of Hgb A1c Primary outcome Definition of renal outcomes
SGLT2i vs placebo
 CANVAS Program RCT Multinational Canagliflozin 300/100 29.0 30–59 7.0–10.5 MACE ≥ 40% eGFR decline, ESRD, renal death
 CREDENCE RCT Multinational Canagliflozin 100 31.4 30–59 6.5–12.0 Renal outcomes Doubing creatinine, ESRD, renal or CV death
 DECLARE-TIMI 58 RCT Multinational Dapagliflozin 10 50.4 <60 6.5–12.0 MACE ≥ 40% eGFR decline, ESRD, renal or CVdeath
 EMPA-REG OUTCOME RCT Multinational Empagliflozin 10/25 37.2 30–59 7.0–9.0 MACE Doubling creatinine, ESRD, renal death
 SCORED RCT Multinational Sotagliflozin 400 16.0 25–60 > 7.0 MACE ≥ 50% eGFR decline, ESRD
 VERTIS-CV RCT Multinational Ertugliflozin 5/15 36.0 30–59 7.0–10.5 MACE Doubing creatinine, ESRD, renal death
GLP-1 RA vs placebo
 ELIXA RCT Multinational Lixisenatide 20 mcg 25.2 30–59 5.5–11.0 MACE (including unstable angina) N/A
 EXSCEL RCT Multinational Exenatide 2 (weekly) 38.4 30–59 6.5–10 MACE ≥ 40% EGFR decline, ESRD, renal death
 HARMONY Outcomes RCT Multinational Albiglutide 30/50 19.2 30–59 > 7.0 MACE N/A
 LEADER RCT Multinational Liraglutide 1.8 45.6 30–59 > 7.0 MACE Doubling of serum creatinine, ESRD
 PIONEER-6 RCT Multinational Semaglutide 14 (oral) 15.9 30–59 N/A MACE N/A
 REWIND RCT Multinational Dulaglutide 1.5 (weekly) 64.8 15–59 < 9.5 MACE ≥ 30% eGFR decline, ESRD, renal death
 SUSTAIN-6 RCT Multinational Semaglutide 0.5/1 (weekly) 25.2 <60 > 7.0 MACE N/A
  1. SGLT2i sodium-glucose cotransporter-2, GLP-1 RA glucagon-like peptide-1 receptor agonist, RCT randomized control study, eGFR estimated glomerular filtration rate, Hgb A1c hemoglobin A1c, ESRD end-stage renal disease, MACE major adverse cardiovascular events, RCT randomized control trial, CV cardiovascular